BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 32027283)

  • 1. [Establishment and Clinical Application of Flow Cytometric Immunobead Array in Detecting Plasma von Willebrand Factor Antigen].
    Yan B; He Y; Lu SQ; Qu L; Xu MQ; Wang Q; Zhao YM; Ruan CG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):235-241. PubMed ID: 32027283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Establishment of Flow Cytometric Immunobead Array for Detecting Plasma Von Willebrand Factor Activity and Its Clinical Application in the Prognosis of Ischemic Stroke].
    Yan B; He Y; Lu SQ; Xu MQ; Wang Q; Zhao YM; Ruan CG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):208-214. PubMed ID: 30738472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a novel flow cytometric immunobead array to quantify VWF: Ag and VWF: GPIbR and its application in acute myocardial infarction.
    Yan B; Xu M; Zhao Y; Guo H; Xia L; Ruan C; Zhao Y
    Eur J Haematol; 2017 Sep; 99(3):207-215. PubMed ID: 28523822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new flow cytometric method for measurement of von Willebrand factor activity.
    Lindahl TL; Fagerberg IH; Larsson A
    Scand J Clin Lab Invest; 2003; 63(3):217-23. PubMed ID: 12817908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of an automated chemiluminescent assay to a manual ELISA assay for determination of von Willebrand Factor collagen binding activity on VWD plasma patients previously diagnosed through molecular analysis of VWF.
    Jousselme E; Jourdy Y; Rugeri L; Négrier C; Nougier C
    Int J Lab Hematol; 2018 Feb; 40(1):77-83. PubMed ID: 28980759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profile of von Willebrand factor antigen and von Willebrand factor propeptide in an overall TIA and ischaemic stroke population and amongst subtypes.
    Tobin WO; Kinsella JA; Kavanagh GF; O'Donnell JS; McGrath RT; Tierney S; Egan B; Feeley TM; Coughlan T; Collins DR; O'Neill D; Murphy S; Lim SJ; Murphy RP; McCabe D
    J Neurol Sci; 2017 Apr; 375():404-410. PubMed ID: 28320178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative evaluation of a new fully automated assay for von Willebrand factor collagen binding activity to an established method.
    Stufano F; Baronciani L; Mane-Padros D; Cozzi G; Faraudo S; Peyvandi F
    Haemophilia; 2018 Jan; 24(1):156-161. PubMed ID: 29168270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
    Favaloro EJ; Thom J; Patterson D; Just S; Dixon T; Koutts J; Baccala M; Rowell J; Baker R
    Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease.
    Favaloro EJ; Mohammed S
    Thromb Res; 2016 May; 141():202-11. PubMed ID: 26743192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry.
    Giannini S; Mezzasoma AM; Leone M; Gresele P
    Haematologica; 2007 Dec; 92(12):1647-54. PubMed ID: 18055988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use.
    Murdock PJ; Woodhams BJ; Matthews KB; Pasi KJ; Goodall AH
    Thromb Haemost; 1997 Oct; 78(4):1272-7. PubMed ID: 9364997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma.
    Lippi G; Franchini M; Salvagno GL; Montagnana M; Poli G; Guidi GC
    J Thromb Thrombolysis; 2008 Oct; 26(2):150-3. PubMed ID: 17786534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between von Willebrand factor (VWF) and VWF antigen II in normal individuals and patients with von Willebrand disease.
    de Romeuf C; Mazurier C
    Thromb Haemost; 1998 Jul; 80(1):37-41. PubMed ID: 9684782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis.
    Veyradier A; Caron C; Ternisien C; Wolf M; Trossaert M; Fressinaud E; Goudemand J
    Haemophilia; 2011 Nov; 17(6):944-51. PubMed ID: 21371195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alloantibody from a patient with severe von Willebrand disease inhibits von Willebrand factor-FVIII interaction.
    Batlle J; Lourés E; Vila P; Hernández MC; Méndez JA; Torea J; Rendal E; Couselo MJ; Filgueira A; López Fernández MF
    Ann Hematol; 1997 Sep; 75(3):111-5. PubMed ID: 9368480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of von Willebrand factor to collagen by flow cytometry.
    Kempfer AC; Silaf MR; Farias CE; Carballo GA; Woods AI; Lazzari MA
    Am J Clin Pathol; 1999 Mar; 111(3):418-23. PubMed ID: 10078119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An enzyme-linked immunosorbent assay (ELISA) for von Willebrand factor antigen (vWf-Ag) in canine plasma.
    Slappendel RJ; Frielink RA; Mol JA; Noordzij A; Hamer R
    Vet Immunol Immunopathol; 1992 Jun; 33(1-2):145-54. PubMed ID: 1632075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel ELISA-based diagnosis of acquired von Willebrand disease with increased VWF proteolysis.
    Rauch A; Caron C; Vincent F; Jeanpierre E; Ternisien C; Boisseau P; Zawadzki C; Fressinaud E; Borel-Derlon A; Hermoire S; Paris C; Lavenu-Bombled C; Veyradier A; Ung A; Vincentelli A; van Belle E; Lenting PJ; Goudemand J; Susen S
    Thromb Haemost; 2016 May; 115(5):950-9. PubMed ID: 26791163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.